VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients

Abstract

This study concerns the expression of biomarkers involved in diverse pathways, such as progression, DNA repair mechanisms and angiogenesis, in order to establish an immunoprofile capable of characterizing sporadic versus familial breast cancers (BCs). The aim was to identify a patient subgroup with a different clinical outcome, which could then be directed towards new targeted therapies. Hierarchical cluster analysis (HCA) was carried out using the immunohistochemical score from tissue microarray sections of an initial cohort of 183 (88 sporadic and 95 familial) patients with invasive BC. For the survival analysis, only those patients with complete follow-up were considered. The HCA revealed a 16-protein immunoprofile, 9 of which represent the core, as was also found when familial and sporadic BCs were analysed individually. The 16-biomarker immunoprofile was able to identify a group of patients (Group 1) with a more aggressive tumour phenotype. Survival analyses showed that VEGF⁺/TWIST1^- patients with familial BC of Group 1 tended to demonstrate a lower DFS than the VEGF^-/TWIST1⁺ sporadic BC patients of Group 2 (p=0.052). Moreover, the entire cohort of VEGF⁺/TWIST1^- patients showed a statistically worse DFS than the patients with VEGF^-/TWIST1⁺ expression (p=0.034). In conclusion, we found that tumour stratification based on an immunoprofile is useful to predict the patient clinical behaviour. In particular, our study indicates that the clustering of tumors on the basis of this immunoprofile suggests the possibility to differentiate familial from sporadic BCs and to clinically select those patients who are more likely to benefit from inhibition of the VEGF pathway. This article is protected by copyright. All rights reserved.

http://ift.tt/2sECiRb